Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
| Autor: | Stellbrink, Hans-Jürgen, Arribas, José R, Stephens, Jeffrey L, Albrecht, Helmut, Sax, Paul E, Maggiolo, Franco, Creticos, Catherine, Martorell, Claudia T, Wei, Xuelian, Acosta, Rima, Collins, Sean E, Brainard, Diana, Martin, Hal |
|---|---|
| Zdroj: | In The Lancet HIV June 2019 6(6):e364-e372 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|